Why Is Dextromethorphan In Auvelity For Depression?

Auvelity is a prescription medicine approved by the FDA in 2022 for adults with major depressive disorder. It combines two drugs that were already on the market for other purposes: bupropion, an antidepressant, and dextromethorphan, the cough suppressant found in many over-the-counter cold medicines. Dextromethorphan is in Auvelity because, at the right dose and paired with bupropion, it acts on brain receptors involved in depression — and bupropion keeps it in the body long enough to matter. That pairing is the whole idea behind the drug.

Why Is Dextromethorphan In Auvelity For Depression?

Dextromethorphan is there to do the antidepressant work. Bupropion is there to make that work possible.

Dextromethorphan belongs to a class of drugs that act on NMDA receptors, a type of glutamate receptor in the brain. Glutamate is the main excitatory chemical messenger in the nervous system. The NMDA receptor has drawn attention in depression research because it is involved in synaptic plasticity — the brain’s ability to adjust the strength of its connections. Standard antidepressants like SSRIs mostly act on serotonin, and they take weeks to show benefit. Drugs that act on the glutamate system were studied partly in hopes of finding faster-acting treatments.

Dextromethorphan also interacts with the sigma-1 receptor, which is thought to help regulate cell stress responses and signaling. Some researchers believe this contributes to its effects. How much each receptor contributes to the antidepressant effect in people is not fully settled.

On its own, dextromethorphan would not work well as an antidepressant. The body breaks it down quickly, largely through an enzyme called CYP2D6. Blood levels fall too fast to sustain an effect. That is where bupropion comes in.

What Does Bupropion Do in the Combination?

Bupropion is a strong inhibitor of CYP2D6. By blocking that enzyme, it slows the breakdown of dextromethorphan and keeps blood levels higher for longer. This is a deliberate pharmacokinetic design — one drug changing how the body handles the other.

Bupropion is also an antidepressant in its own right, approved for major depressive disorder and seasonal affective disorder. So Auvelity contains two active drugs that both have antidepressant activity. The dextromethorphan-bupropion pairing is the first FDA-approved oral antidepressant in decades to work through a mechanism other than monoamine reuptake inhibition alone. That is a meaningful shift in how depression treatment is approached, though it does not mean older drugs are outdated.

One practical consequence of the design: because bupropion raises dextromethorphan levels, the dextromethorphan dose in Auvelity is lower than what you would find in a typical cough medicine. The two drugs are formulated together as an extended-release tablet, taken on a specific schedule.

How Is Auvelity Different From Standard Antidepressants?

The main difference is the target. Most first-line antidepressants — SSRIs and SNRIs — work by increasing serotonin and/or norepinephrine signaling. Auvelity’s dextromethorphan component acts on glutamate and sigma-1 receptors instead.

Another difference is the dosing schedule. Auvelity is typically started as one tablet once daily for a few days, then increased to twice daily. Some clinicians note that twice-daily dosing can be harder to stick with than a once-daily pill, which matters for a condition where consistency affects outcomes.

A third difference is the side effect profile. Auvelity can cause dizziness, headache, drowsiness, dry mouth, and nausea. It also carries the same boxed warning as other antidepressants about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, especially early in treatment. Auvelity is approved for adults only.

What Auvelity is not: it is not a first-line treatment for most people. Clinical guidelines generally place it as an option when other antidepressants have not worked well or are not tolerated. Some clinicians use it earlier, particularly when a faster onset is hoped for. That is a clinical judgment, not a universal recommendation.

Does Auvelity Work Faster Than Other Antidepressants?

The evidence suggests it may act faster than standard antidepressants for some people, but the picture is not simple.

In the clinical trials that supported FDA approval, Auvelity showed improvement in depressive symptoms as early as one to two weeks in some participants, compared with placebo. Standard antidepressants typically take several weeks to show clear benefit. That early separation is notable because faster relief would matter a great deal for people in acute distress.

The caution: early response in a trial does not guarantee the same timeline for every person. Response varies widely. And the trials compared Auvelity to placebo, not head-to-head against an SSRI over the long term. So the claim that it is faster than a specific antidepressant like sertraline or escitalopram is not established by direct comparison. It may be, for some people. We do not have the head-to-head data to say for certain.

What the trials do support is that Auvelity is more effective than placebo in adults with major depressive disorder over the study periods. That is the core finding.

Who Should Not Take Auvelity?

Auvelity is not appropriate for everyone. The FDA label lists several important restrictions.

• People taking MAOIs. Combining Auvelity with a monoamine oxidase inhibitor can cause a dangerous rise in blood pressure. A washout period is required when switching between them.
• People with seizure disorders. Bupropion lowers the seizure threshold. Auvelity should be used cautiously or not at all in people with a history of seizures.
• People with eating disorders. Bupropion is associated with increased seizure risk in people with bulimia or anorexia nervosa.
• People abruptly stopping alcohol or sedatives. Withdrawal can increase seizure risk when bupropion is present.
• People taking certain other drugs. Because bupropion inhibits CYP2D6, it can raise levels of many medications, including some heart drugs, antipsychotics, and other antidepressants. A pharmacist or prescriber needs to review the full medication list.

Auvelity also carries warnings about high blood pressure, angle-closure glaucoma, and serotonin syndrome when combined with other serotonergic drugs. These are not reasons to avoid it categorically — they are reasons for careful screening before starting.

What Should You Know Before Asking About Auvelity?

Auvelity is a real treatment option, not a marketing story. It has FDA approval based on clinical trials, a defined mechanism, and a known side effect profile. It is also not a first choice for most people, and it is not free of risk.

If you are considering it, the conversation with your prescriber should cover: what you have already tried, how you responded, your full medication list, any history of seizures or eating disorders, and your blood pressure. Cost is also worth raising — Auvelity is a brand-name drug, and coverage varies by insurance plan.

Depression is a condition where treatment is often a process of trial and adjustment. Having another mechanism available expands the options. It does not replace the need for a careful, individualized plan. If you are struggling, reaching out to a clinician is the right next step — not waiting to see if things improve on their own.